2024年圣安东尼奥乳腺癌研讨会（SABCS）将于12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS旨在向国际学术界、医师和研究人员提供有关乳腺癌和癌前乳腺疾病等方面的前沿信息。日前，大会公布了摘要标题，【肿瘤资讯】特对LBA Oral Session、General Session、Rapid Fire Session的口头报告研究进行整理，敬请关注。
Late-Breaking Oral Presentations
LB1-01：Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women.
中文标题：可手术乳腺癌患者省略即刻手术或减少手术范围的长期影响：对四项随机试验2,514名女性患者水平的荟萃分析
讲者：Robert Hills, University of Oxford, Oxford, United Kingdom
LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer.
中文标题：MARGOT/TBCRC052：一项随机II期试验，比较新辅助紫杉醇/ margetuximab /帕妥珠单抗（TMP）与紫杉醇/曲妥珠单抗/帕妥珠单抗（THP）在II-III期HER2阳性乳腺癌患者中的疗效
讲者：Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study.
中文标题：PADMA研究：比较一线ET联合哌柏西利 vs标准单药化疗用于具有化疗指征的高危HER2-/HR+转移性乳腺癌患者随机III期试验主要结果
讲者：Sibylle Loibl, German Cooperative Group, Neu-Isenburg, Germany
LB1-04: Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06.
中文标题：DESTINY-Breast06额外分析：根据既往以内分泌治疗为基础的方案疾病进展速度比较德曲妥珠单抗（T-DXd） vs 医生选择的化疗（TPC）的疗效和安全性
讲者：Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California
LB1-05: ROSC (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.
中文标题：在遗传或临床高危HR+/HER2-早期乳腺癌中，根据ET反应（新）辅助nab-PAC周疗 vs 每2周1次sb-PAC，随后每2周1次EC的ROSC：WSG ADAPT-HR+/HER2-化疗试验最终生存结果
讲者：Sherko Kuemmel, German Medical Institute, Limassol, Germany
LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC).
中文标题：SOLTI VALENTINE主要结果：一项新辅助随机II期试验旨在评估HER3-DXd单药或与来曲唑联合用于高危HR+/HER2-早期乳腺癌（EBC）的疗效
讲者：Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.
中文标题：帕博利珠单抗或安慰剂+化疗新辅助治疗，后帕博利珠单抗或安慰剂辅助治疗用于早期三阴性乳腺癌：III期KEYNOTE-522研究探索性生物标志物分析
讲者：Joyce O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas
General Session 1
GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial.
中文标题：Imlunestrant，一种口服选择性雌激素受体降解剂（SERD），单药以及与阿贝西利联合用于既往接受过内分泌治疗（ET）的ER+, HER2-晚期乳腺癌（ABC）：3期EMBER-3试验结果
讲者：Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York
GS1-02: Discussant Harold Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts
GS1-03: Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial.
中文标题：吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛用于未经治疗的HER2阳性转移性乳腺癌（mBC）：3期PHILA试验预设的无进展生存期（PFS）最终分析结果
讲者：徐兵河，中国医学科学院肿瘤医院
GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial.
中文标题：靶向HER2的抗体药物偶联物SHR-A1811用于HER2阳性早期乳腺癌新辅助治疗：一项前瞻性、随机、开放标签、2期试验
讲者：李俊杰，复旦大学附属肿瘤医院
GS1-05: Discussant Aleix Pratt, Hospital Clinic Barcelona, Barcelona, Spain
GS1-06: PRO B – a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients.
中文标题：PRO B——一项评估症状监测用于转移性乳腺癌患者的优越性随机对照试验
讲者：Maria Margarete Karsten, Charité-Universitätsmedizin, Berlin
GS1-07: Discussant Gabrielle Rocque, University of Alabama at Birmingham, Birmingham, Alabama
GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study.
中文标题：降低风险手术与年轻BRCA携带者乳腺癌患者生存期的相关性：一项国际队列研究结果
讲者：Matteo Lambertini, University of Genova, Genova, Italy
GS1-09: OlympiA- Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow.
中文标题：3期多中心、随机、安慰剂对照OlympiA研究的长期随访结果：（新）辅助化疗后奥拉帕利辅助治疗用于携带胚系BRCA1/BRCA2突变和高危HER2-原发性乳腺癌
讲者：Judy Garber, Dana-Farber Cancer Institute, Boston, Massachusetts
General Session 2
GS2-01: Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.
中文标题：70+luminal样早期乳腺癌女性患者特有内分泌治疗或放射治疗（EUROPA）：一项随机3期试验的预先计划中期分析
讲者：Icro Meattini, University of Florence, Florence, Italy
GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
中文标题：“风险良好”的导管原位癌保乳术后仅他莫昔芬治疗：来自NRG Oncology/RTOG 9804和ECOG-ACRIN E5194试验的结果
讲者：Jean Wright, University of North Carolina School of Medicine, Chapel Hill, North Carolina
GS2-03: Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators.
中文标题：术后放疗是否会影响“中等风险”乳腺癌患者总生存？BIG 2-04 MRC SUPREMO随机试验10年结果：代表SUPREMO试验研究者
讲者：Ian Kunkler, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, Scotland
GS2-04: Discussant Elinor Sawyer, King’s College London, London, United Kingdom
GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
中文标题：低风险导管原位癌（DCIS）患者积极监测或手术（±放疗）的早期肿瘤学结果：比较手术与监测伴或不伴内分泌治疗（COMET）研究（AFT-25）
讲者：Eun-Sil Hwang, Duke University School of Medicine, Durham, North Carolina
GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
中文标题：低风险导管原位癌（DCIS）患者积极监测或手术（±放疗）后的患者报告结果：比较手术与监测伴或不伴内分泌治疗（COMET）研究（AFT-25）
讲者：Ann Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts
GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
中文标题：接受保乳术的早期浸润性乳腺癌患者无腋窝清扫 vs腋窝前哨淋巴结活检：Intergroup-Sentinel-Mamma（INSEMA）试验最终主要结果
讲者：Toralf Reimer, Universitätsmedizin Rostock, Rostock, Germany
GS2-08: Discussant Puneet Singh, MD Anderson Cancer Center, Houston, Texas
GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.
中文标题：早期乳腺癌试验协作组（EBCTCG）数据库中206,904名女性超重、肥胖和预后情况
讲者：Hongchao Pan, University of Oxford, Oxford, United Kingdom
GS2-10: A long-term image-derived AI risk model for primary prevention of breast cancer.
中文标题：用于乳腺癌一级预防的长期图像衍生AI风险模型
讲者：Mikael Eriksson, Karolinska Institutet, Solna, Sweden
GS2-11: APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.
中文标题：APOBEC3突变诱导乳腺癌促耐药性基因组改变
讲者：Avantika Gupta, Memorial Sloan Kettering Cancer Center, New York, New York
General Session 3
GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy.
中文标题：ZEST研究循环肿瘤DNA监测分析，一项评估尼拉帕利或安慰剂用于根治性治疗后仍存在残留病灶的三阴性乳腺癌或HER2+BRCA突变乳腺癌患者的随机、3期、双盲研究
讲者：Nicholas Turner, Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom
GS3-02: Discussant Ian Krop, Yale School of Medicine, New Haven, Connecticut
GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer.
中文标题：蒽环类药物对高遗传风险淋巴结阴性HR+/HER2-乳腺癌的影响
讲者：Nan Chen, University of Chicago Medicine, Chicago, Illinois
GS3-04: (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.
中文标题：基于内分泌治疗反应（新）辅助nab-PAC周疗vs每2周1次sb-PAC，随后每2周1次EC用于高遗传或临床风险HR+/HER2-早期乳腺癌：WSG ADAPT-HR+/HER2-化疗试验最终生存结果
讲者：Sherko Kuemmel, German Medical Institute, Berlin, Germany
GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.
中文标题：NSABP B-59/GBG-96-GeparDouze：一项随机、双盲、III期临床试验评估新辅助化疗联合阿替利珠单抗或安慰剂，随后辅助阿替利珠单抗或安慰剂在II期和III期三阴性乳腺癌患者中的疗效
讲者：Charles Geyer, University of Pittsburgh, Pittsburgh, Pennsylvania
GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial.
中文标题：新辅助卡瑞利珠单抗联合化疗（chemo）用于早期或局部晚期三阴性乳腺癌（TNBC）：一项随机、双盲、3期试验
讲者：邵志敏，复旦大学附属肿瘤医院
GS3-07: Discussant Giampaolo Bianchini, Vita-Salute San Raffaele University, Milano, Italy
GS3-08: In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss.
中文标题：在乳腺癌中原位检测单个经典MHC-I基因产物以识别基因和亚型特异性抗原呈递丢失
讲者：Paula Gonzalez-Ericsson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.
中文标题：将真实世界临床和基因组数据进行多模态整合，以预测HR+/HER2-转移性乳腺癌患者CDK4/6抑制剂疗效
讲者：Enrico Moiso, Memorial Sloan Kettering Cancer Center, New York, New York
GS3-10: Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer.
中文标题：对CALGB 40603（Alliance）配对DNA和RNA分析揭示II-III期三阴性乳腺癌分子和预后特征
讲者：Brooke Felsheim, UNC School of Medicine, Chapel Hill, North Carolina
GS3-11: Discussant Fred Howard, University of Chicago Medicine, Chicago, Illinois
Rapid Fire 1
RF1-01: Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance).
中文标题：减重干预（WLI）对肥胖乳腺癌女性代谢和炎症生物标志物的影响：来自乳腺癌减重（BWEL）试验（Alliance）的结果
讲者：Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, Massachusetts
RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
中文标题：哌柏西利+来曲唑 vs紫杉醇周疗与曲妥珠单抗和帕妥珠单抗联合用于HR+/HER2+早期乳腺癌患者新辅助治疗：随机II期TOUCH试验（IBCSG 55-17）主要结果
讲者：Luca Malorni, USL Toscana Centro, Hospital of Prato, Prato, Italy
RF1-03: Three-year event-free survival (EFS) of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer (BOOG 2018-01).
中文标题：多中心、II期、TRAIN-3研究3年无事件生存期（EFS）：评估影像学引导为II-III期HER2+乳腺癌定制新辅助化疗持续时间（BOOG 2018-01）
讲者：Fleur Louis, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands
RF1-04: Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracycline/Taxane Therapy in High-Risk Early Breast Cancer.
中文标题：S0221长期随访和更新结果：比较高风险早期乳腺癌患者采用蒽环/紫杉醇辅助治疗替代剂量方案
讲者：Azka Ali, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois
RF1-05: DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls.
中文标题：良性组织中DNA甲基化模式在同侧和对侧乳房中表现相似，但与匹配的乳腺癌和健康对照组不同
讲者：Saya Dennis, Northwestern University Feinberg School of Medicine, Chicago, Illinois
RF1-06: Association of polygenic-based breast cancer risk prediction with patient management.
中文标题：基于多基因的乳腺癌风险预测与患者管理的相关性
讲者：Katie Johansen Taber, Myriad Genetics, San Francisco, California
RF1-07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.
中文标题：HER2富集早期乳腺癌采用度伐利尤单抗、曲妥珠单抗和帕妥珠单抗无化疗方案（DTP试验）病理学完全缓解（pCR）多因素分析
讲者：Bojana Stefanovska, UT Health Science Center, San Antonio, Texas
Rapid Fire 2
RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial.
中文标题：Alliance A011202临床试验入组患者中新辅助化疗后仍有残留淋巴结阳性乳腺癌患者腋窝淋巴结清扫额外淋巴结病变和病理淋巴结升级的影响因素
讲者：Judy Boughey, Mayo Clinic, Rochester, Minnesota
RF2-02: Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies.
中文标题：早期乳腺癌患者新辅助全身治疗（NST）后腋窝手术——5项新辅助治疗研究中残留微转移的治疗路径和预后影响
讲者：Johannes Holtschmidt, VP Medicine & Research GBG Forschungs GmbH
RF2-03: Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655).
中文标题：初始淋巴结阳性乳腺癌患者新辅助化疗后腋窝超声的诊断性能——来自前瞻性AXSANA注册试验（NCT04373655）的结果
讲者：Steffi Hartmann, University of Rostock, Rostock, Germany
RF2-04: Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients. One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO).
中文标题：乳腺癌患者全乳放疗后超大分割vs常规分割序贯调强放疗：一项随机、对照、3期试验（ULTIMO）1年美容效果
讲者：Melanie Machiels, Universiteit Antwerpen, Antwerp, Belgium
RF2-05: Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study.
中文标题：淋巴结阳性乳腺癌患者TILs、ER状态与放疗获益相关性验证：DBCG研究
讲者：Demet Özcan, Aarhus University Hospital, Aarhus, Denmark
RF2-06: A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices.
中文标题：一项全国性、双盲、III期、随机对照试验（RCT），比较NCORP社区实践中奥氮平和丙氯拉嗪治疗化疗导致的难治性恶心
讲者：Luke Peppone, University of Rochester Medical Center, Rochester, New York
Rapid Fire 3
RF3-01: TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort.
中文标题：TBCRC 056：一项尼拉帕利联合多塔利单抗新辅助治疗BRCA突变或PALB2突变乳腺癌患者的II期研究ER+/HER2-队列结果
讲者：Erica Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts
RF3-02: Efficacy of adjuvant avelumab by PD-L1, tumor infiltrating lymphocytes and residual cancer burden in high-risk triple negative breast cancer: secondary and exploratory endpoints of the phase III A-BRAVE trial.
中文标题：基于PD-L1、肿瘤浸润性淋巴细胞和残余癌症负担分层的高危三阴性乳腺癌患者阿维鲁单抗辅助治疗疗效：III期A-BRAVE试验的次要和探索性终点
讲者：Maria Vittoria Dieci, University of Padua, Padua, Italy
RF3-03: Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy – Final results of BreastImmune-03, a multicenter randomized open-label phase II trial.
中文标题：比较纳武利尤单抗+伊匹木单抗（NIVO+IPI）与卡培他滨用于新辅助化疗后有残留病灶的三阴性乳腺癌患者的疗效——多中心、随机、开放标签、II期BreastImmune-03研究最终结果
讲者：Olivier Trédan, Centre Lèon Bèrard, Lyon, France
RF3-04: NRG-BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer.
中文标题：NRG-BR004：一项评估紫杉醇/曲妥珠单抗/帕妥珠单抗联合阿替利珠单抗或安慰剂作为HER2阳性转移性乳腺癌一线治疗疗效的随机、双盲、III期试验
讲者：Vicente Valero, MD Anderson Cancer Center, Houston, Texas
RF3-05: A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP).
中文标题：新辅助HER2靶向治疗±免疫治疗（帕博利珠单抗）的II期研究（neoHIP）
讲者：Heather McArthur, UT Southwestern Medical Center, Dallas, Texas
RF3-06: Mepitel Film for the Reduction of Radiation Dermatitis in Post-mastectomy Radiation Therapy: Results from Alliance A221803: A Multicenter Phase III Randomized Clinical Trial
中文标题：乳房切除术后放疗中使用Mepitel膜减少放射性皮炎：来自多中心、III期Alliance A221803试验的结果
讲者：Kimberly Corbin, Mayo Clinic, Rochester, Minnesota
RF3-07: ROSCO:Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy.
中文标题：ROSCO（可手术乳腺癌新辅助化疗最佳选择的反应）：一项比较5-氟尿嘧啶、表柔比星和环磷酰胺 vs多西他赛和环磷酰胺新辅助化疗的随机III期、分层生物标志物试验
讲者：Daniel Rea, University of Birmingham, Birmingham, United Kingdom
排版编辑：肿瘤资讯-Elva
苏公网安备32059002004080号
